REFRACTORY NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control CompletedThis completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a common pain reliever boost a cancer drug? early trial underway
Disease control CompletedThis early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side eff…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a common arthritis drug tame CAR-T's dangerous side effects?
Symptom relief CompletedThis phase 2 trial tested whether adding the drug anakinra (Kineret) to standard CAR-T cell therapy could prevent nerve toxicity in 15 people with relapsed or refractory non-Hodgkin lymphoma. Participants received anakinra injections for a week alongside their CAR-T infusion. The…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC